CLOs on the Move

Equiscript

www.equiscript.com

 
Equiscript helps safety net providers better understand and grow their 340B pharmacy business. With a keen eye for detail, our skilled people assist our clients in the design and implementation of a home delivery pharmacy program intended to improve health outcomes by putting much-needed medicines into the hands of those patients in the communities we serve.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.equiscript.com
  • 1360 Truxtun Avenue Suite 300
    North Charleston, SC USA 29405
  • Phone: 843.300.1930

Executives

Name Title Contact Details
Stacie Whitt
General Counsel Profile
Lori Mininger
Senior Director of Legal and Compliance Profile
PollyBeth Hawk
Director and General Counsel Profile

Similar Companies

Laboratoires Vivacy

Hyaluronic Acid Experts - Aesthetics Medecine – Dermo Cosmetic - Intimate Care

REGENCare

💉THE Leader in Regenerative Medicine 👉🏼Head of SSCI & @svlcatl 📞678-568-2309 ♻️We are a green company with one motto: save yourself, save the planet 🌍

Sara Wasserbauer M.D.

Hair Transplant Surgery and medical hair loss treatments by hair surgeon Sara Wasserbauer, M.D.. Medical Hair Restoration services. Medical Hair Loss Treatments, in Walnut Creek, San Jose, San Francisco and Napa, California.(CA)

ORIC Pharmaceuticals

ORIC was established in 2014 with a bold vision of Overcoming Resistance in Cancer. Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time. Our initial project was a small molecule antagonist of the glucocorticoid receptor (GR), which has been implicated in resistance to various treatment modalities—including chemotherapy, immunotherapy, and anti-hormonal therapy—and across multiple cancers. The resulting product candidate, ORIC-101, is now being studied in clinical trials for a range of solid tumors. ORIC-101 and other pipeline programs are a result of rigorous, hands-on experimentation and medicinal chemistry efforts led by our internal team of scientists in biology, medicinal chemistry, DMPK and translational medicine, with assistance from academic collaborators and continued guidance from our founders and board members. This collective team maintains an unwavering focus on improving the lives of patients by tackling the problem of cancer treatment resistance.

Nexelis, a Q² Solutions

On the Forefront of COVID-19 Recognized leader in the COVID-19 field by governmental and non-governmental organizations as the reference assay...